

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



邁博藥業
Mabpharm Limited
迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2181)

VOLUNTARY ANNOUNCEMENT
EXCLUSIVE PROMOTION AGREEMENT WITH JEMINCARE
IN RELATION TO CMAB007 IN CHINA

This announcement is made by Mabpharm Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

EXCLUSIVE PROMOTION AGREEMENT WITH JEMINCARE

The board of directors of the Company (the “**Board**”) is pleased to announce that on April 13, 2023, Taizhou Mabtech Pharmaceutical Limited* (泰州邁博太科藥業有限公司) (“**Taizhou Pharmaceutical**”), an indirect wholly-owned subsidiary of the Company, entered into an exclusive commercialization cooperation agreement in relation to CMAB007 (Omalizumab) in China (the “**Agreement**”) with Jiangxi Jemincare Pharmaceutical Co., Ltd.* (江西濟民可信醫藥有限公司) (“**Jemincare**”), pursuant to which Taizhou Pharmaceutical granted an exclusive promotion right in respect of CMAB007 in China (including Mainland China, Hong Kong, Macau and Taiwan regions) (“**Promotion Service Area**”) to Jemincare. Taizhou Pharmaceutical will continue to possess all the rights and interests in respect of CMAB007 in the Promotion Service Area other than promotion right. On the basis of complying with the provisions of the Agreement, Jemincare shall be entitled to use the trademark(s) of CMAB007 to provide exclusive promotion services in respect of CMAB007 in the Promotion Service Area.

The Company’s product pipeline covers drugs in immunology, allergy, oncology, gastroenterology and other fields. The Company’s sales strategy will be more focused on the sales of relevant drugs in advantageous fields, and it will actively cooperate with companies with rich experience and long-established resources to expedite the introduction of marketing resources and achieve a rapid increase in market share, so as to leverage economies of scale and scaling effect through cooperation. Entering into the Agreement will be conducive to enhancing the brand influence of CMAB007 and provide exponential momentum for rapid growth of sales of the Company’s products.

ABOUT CMAB007 (OMALIZUMAB)

CMAB007 (omalizumab), a recombinant humanized anti-immunoglobulin E (“**IgE**”) monoclonal antibody, is our new drug candidate for treatment of asthma patients who remain inadequately controlled despite medium/high dose of inhaled corticosteroids (“**ICS**”) plus long-acting beta-agonists (“**LABA**”). We believe that, once approved by the National Medical Products Administration (“**NMPA**”) for marketing, it will be the first mAb asthma therapy developed by a domestic company marketed in the domestic market of China. CMAB007 combines with free IgE to form an anti-IgE complex that inhibits the high affinity IgE receptor and thereby prevents the allergic response. The safety and efficacy of CMAB007 have been confirmed by the results of four clinical trials of a total of 824 subjects who have been administered CMAB007, which were the largest clinical trials of Monoclonal antibody treating asthma in China. Based on our clinical trial results, CMAB007 can improve asthma patients’ conditions with lower-dose ICS and reduce the incidence of acute asthma attacks.

The new drug application for CMAB007 has been submitted to the NMPA in October 2021, and it has successfully passed site inspection by the NMPA. It is expected to be approved for commercialization in the second quarter of 2023. We expect that upon commercialization, CMAB007 will be the first home-made omalizumab launched in the domestic market. Given that similar drugs have been approved overseas for urticaria and allergic rhinitis indications and are developing to address food allergy indications, we will expedite the clinical and registration work of CMAB007 for these indications to capture the huge allergic disease market demand in China and bring more economical and efficient therapeutic alternatives to more than 5 million patients with allergic diseases in China.

ABOUT JEMINCARE

Jiangxi Jemincare Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Jiangxi Jemincare Group Co., Ltd.* (江西濟民可信集團有限公司) (“**Jemincare Group**”). Founded in 1999, Jemincare Group is a leading universal health focused conglomerate in China that provides reliable protection to human health through constant upgrade of products, technologies and services. It has achieved fruitful results in the fields of nephropathy, tumor, cardiovascular and cerebrovascular diseases, respiration and pain, with its products sold to more than 30 countries and regions.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain approval for, develop or ultimately market, CMAB007 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Hong Kong, April 13, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Wang Hao, Mr. Tao Jing, Mr. Li Yunfeng, and Dr. Li Jing as executive Directors; Mr. Jiao Shuge and Mr. Guo Jianjun as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun and Mr. Leung, Louis Ho Ming as independent non-executive Directors.

* For identification purpose only